The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class Ib molecules) in combination with peptide antigens for the treatment of neuromyelitis optica (NMO). The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating neuromyelitis optica (NMO).
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class Ib molecules) in combination with peptide antigens for the treatment of Parkinson's disease. The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating Parkinson's disease.
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 14/74 - Major histocompatibility complex [MHC]
3.
MHC IB-MEDIATED ISLET-ANTIGEN-SPECIFIC IMMUNOSUPPRESSION AS A NOVEL TREATMENT FOR TYPE 1 DIABETES
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class Ib molecules) in combination with peptide antigens for the treatment of type 1 diabetes (T1D). The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating type 1 diabetes (T1D).
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The present invention concerns genetically modified immune cells for the treatment of tumors and autoimmune diseases, wherein said modified immune cells are armed with innovative chimeric activating receptors directed to immune checkpoint (IC) ligands.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
5.
THERMOANALYTIC DETERMINATION OF ALKALI METALS AND/OR ALKALINE EARTH METALS AND/OR RELATED METALS
G01N 25/48 - Investigating or analysing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
6.
A METHOD AND SYSTEM FOR MEASURING A MODIFIED PROPERTY OF A SAMPLE COMPRISING MAGNETIC PARTICLES IN LIQUID SUSPENSION
A method for measuring a modified property of a sample comprising magnetic particles in suspension using time variable magnetic fields, wherein the method comprises applying a time-varying magnetic excitation field, the excitation field having an excitation amplitude and an excitation frequency, and an offset magnetic field to the sample, such that the magnetic particles are driven into a non-linear magnetization response regime; recording a non-linear magnetization response of the sample for obtaining a signal metric indicative for a phase of a higher harmonic with respect to the excitation frequency in the non-linear magnetization response; and determining a measurement signal indicative of the modified property, the measurement signal being based on the signal metric obtained for the sample and the same signal metric obtained for a reference sample without the modified property, the reference sample also comprising the magnetic particles in suspension.
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
G01N 27/74 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
LEIBNIZ-INSTITUT FÜR NATÜRSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE – HANS-KNÖLL-INSTITUT (Germany)
FRIEDRICH-SCHILLER-UNIVERSITÄT JENA (Germany)
JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (Germany)
LEIBNIZ-INSTITUT FÜR VIROLOGIE (Germany)
Inventor
Brakhage, Axel
Kloss, Florian
Hortschansky, Peter
Preusske, Nils
Schmidt, Franziska
Schubert, Ulrich
Schubert, Stephanie
Behnke, Mira
Adermann, Franziska
Backes, Simone
Gasteiger, Georg
Gabriel, Gülsah
Beck, Sebastian
Abstract
The present invention relates to functionalized nano- or microparticles of suitable size and shape, comprising a nano- or microparticle and at least one virus-binding peptide and/or virus-binding small molecule immobilized onto the surface of the nano- or microparticle. These nano- or microparticle forms aggregates with targeted viral particles to initiate phagocytosis, thereby achieving viral clearance. The present invention further relates to uses of the functionalized nano- or microparticles in virus detection, therapy and diagnosis.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
C07K 17/08 - Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
The present invention relates to compounds and their use in the treatment of lesions, in tissue regeneration and/or tissue engineering. The compounds act as substrates for enzymes having transglutaminase activity and are suitable for their immobilization on extracellular substrates or matrices.
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class Ib molecules) in combination with peptide antigens for the treatment of Parkinson's disease. The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating Parkinson's disease.
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHO) molecules (also named MHO class lb molecules) in combination with myelin-associated peptide antigens for the treatment of multiple sclerosis (MS), MOG antibody disease and MOG antibody positive neuromyelitis optica. The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHO class lb molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating multiple sclerosis (MS), MOG antibody disease and MOG antibody positive neuromyelitis optica.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
11.
MHC IB-MEDIATED AQUAPORIN 4 (AQP4)-SPECIFIC IMMUNOSUPPRESSION AS A NOVEL TREATMENT FOR NMO
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class Ib molecules) in combination with peptide antigens for the treatment of neuromyelitis optica (NMO). The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating neuromyelitis optica (NMO).
The invention refers to a substituted aromatic dicarbonic acid amide compound according to formula I for use in the treatment of cancer, in particular human and/or rodent cancer. Furthermore, the present invention relates to a pharmaceutical composition comprising a compound according to formula I for use in the treatment of cancer and to the use of a compound of formula I for inducing phospholipid dependent ferroptosis in an in vitro cell sample.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
TREATMENT OF SPINAL MUSCULAR ATROPHY (SMA) AND OTHER MOTOR NEURON DISEASES BY CAUSING PRESYNAPTIC EXPRESSION OF A HYBRID MOLECULE OF MUNC13-1 AND SYNAPTOPHYSIN3'UTR TO ENHANCE MUNC13-1 EXPRESSION
This application includes a mammalian mRNA expression construct for producing a protein or polypeptide, the mammalian mRNA expression construct including a modified Munc13-1 molecule.
A01K 67/0275 - Genetically modified vertebrates, e.g. transgenic
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
14.
MODULATION OF PRESYNAPTIC PATHOLOGY WITH MUNC13-1 LOCAL TRANSLATION
This application includes a mammalian mRNA expression construct for producing a protein or polypeptide, the mammalian mRNA expression construct including a modified Munc13-1 molecule.
A01K 67/0275 - Genetically modified vertebrates, e.g. transgenic
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
15.
MULTIVALENT SINGLE-PARTITE ANTIBODIES FOR DUAL-ANTIGEN RESTRICTED IMMUNOTHERAPY
The present invention relates to antibody constructs and such constructs for use as a medicament and in immunotherapy to treat cancer, or mixed tumours, benign tumours, or allergic diseases, or infection diseases, or autoimmune diseases. Moreover, the present invention relates to nucleic acid molecule(s) encoding said antibody constructs. The present invention also relates to vectors comprising the nucleic acid molecule(s). Furthermore, the present invention relates to pharmaceutical compositions comprising said antibody constructs. Moreover, the present invention relates to diagnostic compositions in vivo comprising said antibody constructs. Furthermore, the present invention relates to a diagnostic kit in vitro. Moreover, the present invention relates to a kit comprising said antibody constructs.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
The present invention relates to a nanodrone, a method of operating a nanodrone, and a system for operating a nanodrone. The nanodrone comprises a substrate extending perpendicular to a normal direction and two or more nanoantennas arranged on and/or in the substrate. Each of the two or more nanoantennas exhibits an optically addressable resonance at a respective resonance wavelength. The two or more nanoantennas comprise a first nanoantenna and a second nanoantenna, each being configured to scatter circularly polarized light at the respective resonance wavelength that is incident on the nanoantenna along the normal direction such that photons of the scattered light have a mean wavevector (I) and (II) in a plane perpendicular to the normal direction for left- and right-circularly polarized light, respectively, with i=1 for the first nanoantenna and i=2 for the second nanoantenna. The mean wavevector (III) with ji=L or R is non-zero. The mean wavevector (IV) with (V) for ji=R and (VI) for ji=L is substantially zero or substantially anti-parallel to (III). At least one of (VII) and (VIII) is substantially parallel or substantially anti-parallel to one of (IX) and (X).
G02B 6/10 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type
B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
The present invention relates to a modified human lymphocyte containing and expressing a recombinant nucleic acid or a set of recombinant nucleic acids encoding at least one positive regulator of autophagy. The modified human lymphocyte according to the invention may further contain and express a recombinant nucleic acid or a set of recombinant nucleic acids encoding a T-cell receptor or a chimeric antigen receptor. The invention also relates to methods of producing such modified human lymphocytes, pharmaceutical compositions comprising the same, as well as their uses in medicine and for methods for the treatment of cancer including the immunotherapeutic treatment of cancer.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
18.
STRATEGIES TO TARGET EXTRACELLULARLY ACCESSIBLE RAS PROTEIN
The invention is based on the finding of extracellular accessible Ras protein on cancer cells. The invention provides an Antigen Binding Protein (ABP), such as an antibody or a chimeric antigen receptor (CAR), wherein the ABP comprises at least a first antigen binding domain capable of binding to an extracellular Ras antigen. Further provided are isolated nucleic acids and expression constructs for expressing the ABP according to the present invention, as well as recombinant host cells expressing an ABP according to the present invention. The invention also relates to pharmaceutical compositions, pharmaceutical combinations, compounds for use in medicine, and compounds for use in the diagnosis, prevention and/or treatment of cancer. Finally, the present invention pertains to a combination of an ABP, a CAR, an isolated nucleic acid, an expression construct, a recombinant host cell, or a pharmaceutical composition as defined herein, and a chemical compound, such as a cereblon (CRBN) inhibitor, or a polar organic solvent like DMSO, for use in a method of diagnosis, prevention and/or treatment of cancer.
The invention concerns a system for checking whether a protein of interest (POI) can act as a substrate, in particular a favorable substrate, for an enzyme selected from an E3-ubiquitin ligase, a SUMO E3 ligase, a deubiquitinating enzyme, a kinase or a phosphatase in a eukaryotic cellular environment, wherein the system comprises a first recombinant protein comprising an amino acid sequence of the selected enzyme and an amino acid sequence of a first binding protein of a dimerization system, a second recombinant protein comprising an amino acid sequence of the POI, an amino acid sequence of a reporter protein and an amino acid sequence of a second binding protein of the dimerization system and a ligand of the dimerization system.
C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving enzymes not classifiable in groups
C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
20.
MATRIX METALLOPROTEINASE 13 SENSITIVE PEPTIDES AND SENSORS
The present invention relates to diagnostic MMP-13 sensors, MMP-13 sensitive peptides and related kits. The invention further relates to methods and medical uses involving said sensors, peptides or kits, such as methods for diagnosing cancer or periodontitis in a subject, methods for determining MMP-13 activity as well as the use of the peptide in the treatment of diseases that are related to an increased MMP-13 activity.
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
The present invention relates to diagnostic furin sensors, respective furin sensitive peptides and related kits. The invention further relates to methods and medical uses involving said sensors, peptides or kits, such as methods for diagnosing cancer (particularly HNSCC), in a subject, as well as to methods for determining furin activity.
Invasive fungal disease (IFD) constitutes an increasing health concern due to growing numbers of patients at risk for opportunistic fungal infections. Among the fungi capable of inducing opportunistic infections the yeast Candida albicans is clinically the most important. Immune evasion proteins like the pH-regulated antigen 1 (Pra1) and the translation elongation factor 1 (Tef1), which are expressed on the fungal surface and are also secreted, are major drivers of pathogenicity. Therefore, novel monoclonal antibodies (mAb) binding these proteins have been developed. In an in vivo mouse model of high-dose septic C. albicans infection, therapeutic application of mAb against Pra1 reduced clinical symptoms of the disease. Prophylactically, mAb against Tef1 protected mice from clinical disease and prolonged survival. The mABs of the present invention may also be efficacious in patients at risk or with already established IFD.
Provided is a block copolymer comprising a polymer block (A) which comprises repeating units of formula (I) and a polymer block (B) which comprises repeating units of formula (II),
Provided is a block copolymer comprising a polymer block (A) which comprises repeating units of formula (I) and a polymer block (B) which comprises repeating units of formula (II),
Provided is a block copolymer comprising a polymer block (A) which comprises repeating units of formula (I) and a polymer block (B) which comprises repeating units of formula (II),
wherein R1 is methyl or ethyl, and R2 represents a group —CH2—CH2-phenyl. The copolymer of the present invention allows a rapid thermoresponsive inverse gelation to be achieved, yielding a hydrogel with viscoelastic solid-like properties, as well as shear thinning, rapid structure recovery and good strain resistance properties. The hydrogel can be favorably used in 3D printing applications.
The present invention relates to a compound comprising a multimer, preferably a dimer, of peptides or peptide analogues each comprising the amino acid sequence X1X2LGX3X4 and a linker connecting the peptides or peptide analogues, and pharmaceutical compositions and kits comprising said compound. The present invention further relates to the compound for use in the treatment of a Hepatitis B virus (HBV) infection or a liver disease caused by HBV. The present invention also relates to a method of the treatment of a HBV infection or a liver disease caused by HBV.
The present invention relates to a recombinant proteinaceous binding molecule wherein an Fc fragment is used as fusion partner and combined it with the hemibody technology. Furthermore, the invention relates to a heterodimeric recombinant proteinaceous binding molecule, as well as a method for producing the same, its use and a nucleic acid molecule encoding the recombinant proteinaceous binding molecule. The invention in particular provides a proteinaceous binding molecule that is capable of mediating target cell restricted activation of immune cells.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
26.
DEVICE FOR ENDOVASCULAR DRUG DELIVERY AND USE THEREOF
The present invention relates to a device for endovascular drug delivery, preferably an implant for endovascular drug delivery. The present invention further relates to a device for use in a method of preventing or treating a neurological disease, an oncological disease, a cardiological disease, a vascular disease, an immunological disease, a carcinoid, an infectious disease, and/or an edema.
The present invention relates to novel monoclonal anti-human-GDF-15 antibodies, pharmaceutical compositions, kits, methods and uses and the cell lines capable of producing the monoclonal antibodies described herein. The present invention further relates to novel antibodies to human GDF-15 capable of inhibiting cancer growth.
The present invention provides novel antibodies, fragments or derivatives thereof – as well as respective (medical) uses of those compounds, such as their use as a coagulant, and/or their use in the treatment or prevention of a haemorrhagic condition.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
29.
KIT FOR COMBINATION THERAPY OF TUMOR DISEASES AND/OR INFECTIONS
The present invention relates to a kit of active pharmaceutical ingredients comprising (1) a fusion component comprising an agent, which increases the level of reactive oxygen species (ROS), such as Aplysia punctata ink toxin (APIT), and a targeting sequence, and (2) a prodrug or a proreporter comprising phenylboronic acid or phenylboronic ester derivatives. The present invention relates to said kit of pharmaceutical compositions for use in the diagnosis, prevention and/or treatment of proliferative diseases, viral and/or non-viral infections. The present invention further relates to a method of diagnosis, prevention and/or treatment of a proliferative disease, a viral infection and/or a non-viral infection.
A61K 47/51 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention provides a binding molecule that specifically binds TNFR2, but not TNFR1. Preferably the binding molecule is an FcγR-independent agonist of TNFR2 and more preferably has a valency of at least two for binding TNFR2. The binding molecules have a variety of uses including diagnostic and therapeutic. The ability of the binding molecules to be able to modulate immune responses means that they are particularly suited for treating autoimmune diseases, or inflammatory conditions.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.
FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (Germany)
Inventor
Groeber-Becker, Florian
Schilling, Bastian
Beyersdorf, Niklas
Kerkau, Thomas
Abstract
The present invention relates to solid microbeads having an anti-CD28 monoclonal antibody immobilized thereto for use in the local treatment of malignant melanoma, wherein the anti-CD28 monoclonal antibody binds to an epitope on CD28 outside the C" D loop. The present invention further relates to methods for the local treatment of malignant melanoma comprising the administration of said microbeads.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The invention refers to an implant device, in particular to a pubic symphysis implant device, and to an implant system comprising two such implant devices. The implant device of the invention comprises a bent body comprising a curved middle portion and two lateral arms extending away from the middle portion and being mutually joined by the middle portion, and at least one guiding element defining at least one guiding path along which a tensioning element can be guided. The invention further refers to method of fixating together a first bone or bone part and a second bone or bone part, for example for re-joining a disjoined pubic symphysis, using such an implant system, in particular by placing each of the two implant devices on corresponding bones or bone parts and by pulling the two implant devices towards each other by tensioning a tensioning element guided along the at least one guiding path of each of the two implant devices.
The present invention relates to novel protease-sensitive peptides, related compounds or salts thereof having the structure Den-R-NH-Pep (wherein Den is a denatonium residue and Pep designates a protease-sensitive peptide) as well as bioresponsive sensors comprising same, which may be used for diagnostic purposes, in particular for detection of inflammation, as well as to related methods and uses.
A device for fabricating a perfusable three-dimensional tissue construct includes a chamber in which the tissue construct may be cultivated, the chamber including an inlet and an outlet for perfusing the tissue construct, and a sacrificial scaffold fixed in the chamber. The sacrificial scaffold includes a thermo-responsive polymer, the thermo-responsive polymer being not dissolvable in water at human body temperature and becoming dissolvable in water at a temperature below 30° C. The sacrificial scaffold includes at least one filament extending from the inlet to the outlet such that dissolution of the sacrificial scaffold provides for a liquid channel from the inlet to the outlet. The sacrificial scaffold seals the inlet and/or the outlet such that dissolution of the sacrificial scaffold after receiving a cultivation matrix in the chamber provides for a liquid channel from the inlet to the outlet through the cultivation matrix. Methods of use and manufacture are also disclosed.
The present invention discloses a therapeutic gas release system for oral administration comprising a therapeutic gas releasing compound A, and a therapeutic gas release triggering compound B, wherein compound A and B are separated from each other by an inner septum during storage of the system, wherein compound A and B are surrounded by an outer membrane, which is a gas-permeable and water- and solid-impermeable membrane, preferably a silicone membrane, and wherein therapeutic gas release from the system is activated before oral administration by breaking the inner septum. The therapeutic gas released from the system of the present invention is suitable for the treatment of (inflammatory) diseases of the gastrointestinal tract.
The present invention relates to oligomeric and oligovalent anti-CD40 antibody variants displaying high intrinsic, thus FcγR-indpendent, agonistic activity. The invention more specifically relates to tetra-, penta-, hexa-, hepta-, octa-, nona-, deca- and docevalent or even higher valency antibody constructs with FcγR- independent activity composed of CD40-specific Fab- and/or scFv domains and/or sdAb domains and an dimeric, trimeric, tetrameric oligomerization scaffold preferentially Fc, IgG molecule or trimerization domain of TNC. The invention also relates to the enforced oligomerization of several anti-CD40 IgG molecules, that can be achieved in a stoichiometric fashion by genetic engineering, that confers strong FcγR-independent agonism, and to the fact that the idiotype of the anti-CD40 antibody has no major effect on the autonomous agonism of oligovalent anti-CD40 variants.The invention also relates to methods of producing such oligomeric and oligovalent anti-CD40 antibody constructs, pharmaceutical compositions comprising the same, as well as their uses for treating cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to the use of carbon monoxide for the preservation of gametes. The present invention provides for means and methods for the preservation of gametes. An inventive method comprises the steps of a) providing gametes or a sample comprising said gametes in a container and b) contacting said gametes in said container with carbon monoxide. The present invention also provides for the use of carbon monoxide in treating and/or preventing a disease, for example a disease caused by or linked to elevated DNA fragmentation, oxidation-reduction potential of gametes, and/or a disease of gametes caused by or linked to elevated ROS levels. Also provided is carbon monoxide for use in preventing congenital abnormality and/or aneuploidy but also the use of carbon monoxide for use in treating a disease caused by and/or linked to elevated DNA fragmentation and/or oxidation-reduction potential of gametes. The present invention furthermore relates to a method for treating congenital abnormality or aneuploidy comprising contacting carbon monoxide gas to gametes of a patient in need thereof. Thus, the inventive means, methods, and uses ensure the preservation of gametes in a functional/intact state and, thus, to safeguard a maintained and/or improved gamete quality. Such carbon monoxide treated/carbon monoxide exposed gametes are, thus, particularly useful in reproductive technologies, for example in in vitro reproductive technologies, including assisted reproductive technologies in humans and/or in (artificial) insemination techniques in animals.
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
A61P 15/10 - Drugs for genital or sexual disordersContraceptives for impotence
A61K 9/00 - Medicinal preparations characterised by special physical form
39.
RECEPTACLE, DEVICE FOR RELEASING CARBON MONOXIDE, TREATMENT SYSTEM, SET FOR TREATING LIVING CELLS, METHOD OF TREATING A MAMMAL, AND CARBON MONOXIDEΞ
The present invention relates to a receptacle (10) configured to be inserted into a human body and/or an animal body, including a housing (12) and a chamber (14) defined within the housing (12). The chamber (14) is configured to receive a main substance (42) configured to selectively emit carbon monoxide after being activated by an activation substance (44). The chamber (14) is enclosed by a wall (16) of the housing (12) which is permeable to the carbon monoxide emitted by the main substance (42) such that the receptacle (10) can release the carbon monoxide emitted by the main substance (42) to an environment. The receptacle (10) is configured such that the activation substance (44) can be introduced into the chamber (14) from outside of the housing (12), in a state in which the main substance (42) is already arranged within the chamber (14). The present invention further relates to a device (40) for selectively releasing carbon monoxide, a treatment system (60; 80) and a set for treating biological cells, preferably living cells, a method for treating a mammal, a use of carbon monoxide, and method of treating biological cells.
The present invention relates to an anti-GDF15 antibody and to a dosage regimen for the treatment of cancer in a human patient using the anti-GDF15 antibody. The present inventors identified a mechanism by which GDF-15 blocks adhesion and transgression of predominantly T-lymphocytes into tissues. Hence, a novel treatment approach has been established by the present invention that facilitates effector T cell entry into tumor tissue upon blockage of GDF-15 using the antibody of the present invention thereby allowing the treatment of cancer in human patients.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
41.
BIOCOMPATIBLE COMPOSITE MEMBRANE, METHOD FOR FABRICATING THE MEMBRANE, BIOREACTOR AND METHOD FOR INVESTIGATING CELLS ATTACHED TO THE BIOCOMPATIBLE COMPOSITE MEMBRANE
In various embodiments a biocompatible composite membrane for in vitro cell culturing comprising a first material, which is non-water soluble and a water soluble second material is provided, wherein the composite membrane comprises a porous scaffold and a filling layer, the scaffold comprising the first material and the filling layer comprising the second material. Further, a method for fabricating the membrane, a bioreactor for use of the membrane in cell-stretch experiments and a corresponding method for investigating cells attached to the biocompatible composite membrane are also provided.
The present invention relates to therapeutical uses of non-classical major histocompatibility complex (MHC), also known as MHC class Ib molecules in combination with defined peptides. The invention more specifically relates to targeted immunomodulatory effects of defined peptides in combination with proteins comprising one or more domains of a non-classical MHC class Ib molecule or in combination with molecules that interfere with the interaction of MHC class Ib molecules and their receptors. The invention also relates to methods of producing such proteins, pharmaceutical compositions comprising the same, as well as their uses for treating medical conditions in which antigen-specific immune reactions are beneficial, including cancer and infectious diseases, or harmful, including autoimmune diseases, organ/tissue rejection, immune reactions towards pharmaceutical compounds or reproductive disorders. Moreover, as the invention reveals a novel mode of action for MHC class Ib molecules during antigen-specific tolerance induction, it also relates to methods for interfering with this mechanism in situation where induction of antigen-specific immune tolerance is wanted, but physiologically prevented by said mechanism.
C07K 14/74 - Major histocompatibility complex [MHC]
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention relates to methods for predicting the probability of survival of a human melanoma cancer patient based on levels of human GDF-15, and to apparatuses and kits which can be used in these methods.
The present invention relates to multivalent anti-Fn14 antibody constructs that show memTWEAK- mimicking agonism. The invention more specifically relates to tetra-, hexa- and octavalent antibody constructs composed of Fn14-specific Fab- and scFv domains with FcγR-independent activity. The invention also relates to methods of producing such multivalent anti-Fn14 antibody constructs, pharmaceutical compositions comprising the same, as well as their uses for treating cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
46.
MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USESTHEREOF FOR TREATING CANCER CACHEXIA AND CANCER
The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine antibodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.
The invention relates a novel isolated recombinant fibrinogen and to a eucaryotic cell producing said novel recombinant fibrinogen, as well as to a fibrin sealant and a fibrin sealant kit comprising the novel isolated recombinant fibrinogen. Furthermore, the present invention relates to a new method for the production of recombinant fibrinogen using eucaryotic cells, and to a new method for identifying novel recombinant fibrinogen variants with reduced sensitivity to proteolytic cleavage by plasmin without losing their suitability as fibrinogen component in a fibrin sealant.
METHOD AND MOLECULES FOR REDUCING AXONAL TAU PROTEIN ACCUMULATION THROUGH BLOCKING OF HNRNP R-MEDIATED MAPT MRNA TRANSPORT FOR TREATMENT OF ALZHEIMER'S DISEASE
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
49.
COMBINATION THERAPY OF ATRA OR OTHER RETINOIDS WITH IMMUNOTHERAPEUTIC AGENTS BINDING TO BCMA
The invention relates to combination therapies of ATRA and other retinoids with immunotherapeutic agents binding to BCMA such as CAR-T cells capable of binding to BCMA, antibodies capable of binding to BCMA or antibody fragments capable of binding to BCMA. According to the invention, these combination therapies can be advantageously applied to the treatment of cancers such as multiple myeloma and can also be applied to the treatment of antibody-mediated autoimmune diseases. The combination therapies in the treatment of cancers according to the present invention are advantageous, for instance, because retinoids such as ATRA can upregulate BCMA mRNA levels as well as BCMA protein levels in cancer cells, such that the cancer cells can be more effectively targeted by immunotherapeutic anticancer agents capable of binding to BCMA such as CAR-T cells capable of binding to BCMA, antibodies capable of binding to BCMA or antibody fragments capable of binding to BCMA.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention relates to a composition comprising a metal-organic framework, one or more emulsifier(s), one or more lipid(s) and one or more co-emulsifier(s). Furthermore, the present invention relates to a method for preparing a microemulsion in response to a physical- and/or chemical stimulus and to a method for increasing the solubility of a pharmaceutically active ingredient in a solvent and/or for improving the bioavailability of a pharmaceutically active ingredient and/or for preparing a self-microemulsifying drug delivery system.
The invention relates to the immunomodulatory features of dasatinib and other tyrosine kinase inhibitors towards genetically modified immune cells. The invention encompasses the indication of dasatinib and other tyrosine kinase inhibitors as an immune cell inhibitor as well as an enhancer of immune cells depending on the dosing and schedule of treatment, the administration routes, the susceptible receptor variants and the treatable cell types which can be used for immunotherapy.
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class lb molecules) in combination with myelin-associated peptide antigens for the treatment of multiple sclerosis (MS), MOG antibody disease and MOG antibody positive neuromyelitis optica. The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class lb molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating multiple sclerosis (MS), MOG antibody disease and MOG antibody positive neuromyelitis optica.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
53.
MHC IB-MEDIATED AQUAPORIN 4 (AQP4)-SPECIFIC IMMUNOSUPPRESSION AS A NOVEL TREATMENT FOR NMO
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class Ib molecules) in combination with peptide antigens for the treatment of neuromyelitis optica (NMO). The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating neuromyelitis optica (NMO).
The present invention relates to a lymphocyte, modified to exhibit a reduced BCL2L11 level and/or an increased BATF3 level. The invention also relates to a method for producing such lymphocytes and a pharmaceutical composition comprising such lymphocytes. The lymphocytes and the pharmaceutical composition of the present invention may be used in methods for treating a disease in a patient.
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class lb molecules) in combination with peptide antigens for the treatment of type 1 diabetes (T1D). The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class lb molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating type 1 diabetes (T1D).
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 37/00 - Drugs for immunological or allergic disorders
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 14/74 - Major histocompatibility complex [MHC]
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class lb molecules) in combination with peptide antigens for the treatment of Parkinson's disease. The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class lb molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating Parkinson's disease.
The present invention relates to a siglec-6-binding polypeptide that comprises or consists of an antibody or a fragment thereof binding siglec-6 or comprises or consists of a siglec-6-binding chimeric antigen receptor (CAR), a polynucleotide encoding the siglec-6-binding polypeptide, an expression vector comprising the polynucleotide, an immune cell comprising the polypeptide, polynucleotide or expression vector, a method for producing immune cells and a pharmaceutical composition comprising immune cells. The immune cells and the pharmaceutical composition of the present invention may be used in methods for treating a disease, such as cancer, in a patient.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Abstract: The invention generally relates to the treatment of cancer with FLT3 targeting agents and kinase inhibitors. In particular, the invention relates to adoptive immunotherapy of Acute Myeloid Leukemia (AML) with chimeric antigen receptor (CAR)-modified T cells specific for FMS-like tyrosine kinase (FLT3) in combination with FLT3 inhibitors.
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
59.
A METHOD AND SYSTEM FOR MEASURING A MODIFIED PROPERTY OF A SAMPLE COMPRISING MAGNETIC PARTICLES IN LIQUID SUSPENSION
A method for measuring a modified property of a sample comprising magnetic particles in suspension using time variable magnetic fields comprises the steps of: applying a time-varying magnetic excitation field, the excitation field having an excitation amplitude and an excitation frequency, and an offset magnetic field to the sample, such that the magnetic particles are driven into a non-linear magnetization response regime; recording a non-linear magnetization response of the sample for obtaining a signal metric indicative for a phase of a higher harmonic with respect to the excitation frequency in the non- linear magnetization response; and determining a measurement signal indicative of the modified property, the measurement signal being based on the signal metric obtained for the sample and the same signal metric obtained for a reference sample without the modified property, the reference sample also comprising the magnetic particles in suspension.
G01N 27/74 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
The disclosure includes a system and method for imaging cells. The method includes: labeling transfected one or more cells with a dye; exciting the dye with an energy source, wherein the dye is configured to emit an emission light; imaging one or more portions of the transfected one or more cells with a sensor, for a predetermined exposure time, a plurality of times to form a plurality of images; classifying each image of the plurality of images into a first group of images above a predetermined threshold for a number of photons per image or a second group of images below the predetermined threshold the number of photons per image; and determining whether the emission energy is from one or more independently emitting quantum systems based on the measured emission, the tracked locations of the one or more portions and the fluorescence trajectory.
The present invention relates to a polypeptide encoding a SLAMF7-binding chimeric antigen receptor (CAR), a polynucleotide encoding the SLAMF7-binding CAR polypeptide, a recombinant immune cell (preferably recombinant lymphocyte, more preferably recombinant T cell) comprising the polynucleotide, a method for producing recombinant immune cells and a pharmaceutical composition comprising recombinant immune cells. The recombinant immune cells and the pharmaceutical composition of the present invention may be used in methods for treating cancer in a patient thereby providing an improved treatment regimen. The inventors of the present application demonstrated that SLAMF7 CAR T-cells prepared by Sleeping Beauty gene transfer confer superior anti-myeloma efficacy in vivo compared to SLAMF7 CAR T-cells prepared by lentiviral gene transfer. Hence, SLAMF7 CAR T-cells that are prepared by virus-free SB gene transfer possess greater anti-myeloma efficacy and therapeutic potential, which leads to significantly improved clinical activity, and significantly improved clinical outcome.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Technion Research and Development Foundation Ltd. (Israel)
Julius-Maximilians-Universität Würzburg (Germany)
Inventor
Segev, Mordechai
Hofling, Sven
Klembt, Sebastian
Dikopoltsev, Alexander
Harder, Tristan
Lustig, Eran
Lumer, Yaakov
Abstract
A laser source is presented a plurality of unit cells of a selected number of partially physically coupled lasing units arranged within a plane and configured to form a topological structure, wherein each of the lasing units is configured to emit radiation component substantially perpendicular to said plane, said plurality of the unit cells comprising at least a first sub-array of the unit cells located in a first region interfacing with a second region of a different type than said first region, thereby defining an arrangement of optically coupled lasing units along an interface region between the first and second adjacent regions, forming at least one topological state along a topological path within said interface region.
The invention refers to a substituted aromatic dicarbonic acid amide compound according to formula I for use in the treatment of cancer, in particular human and/or rodent cancer. Furthermore, the present invention relates to a pharmaceutical composition comprising a compound according to formula I for use in the treatment of cancer and to the use of a compound of formula I for inducing phospholipid dependent ferroptosis in an in vitro cell sample.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH (Germany)
JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (Germany)
Inventor
Beisel, Chase
Jiao, Chunlei
Sharma, Cynthia Mira
Dugur, Gaurav
Abstract
The present invention relates to methods for detecting at least one sensed RNA in a cell, tissue, and/or sample using at least one non-naturally occurring tracrRNA specifically hybridizing with said sensed RNA and at least one tracrRNA-dependent CRISPR nuclease enzyme binding to at least one target nucleic acid, as well as respective systems and diagnostic and therapeutic uses thereof.
iiii = L is substantially zero or substantially anti-parallel to (III). At least one of (VII) and (VIII) is substantially parallel or substantially anti-parallel to one of (IX) and (X).
G02B 6/10 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type
The invention relates to antibodies and derivatives thereof such as bispecific antibodies and chimeric antigen receptors (CARs) with affinity matured and/or humanized targeting domains specific to the ROR2 antigen. The invention encompasses the nucleic acids and vectors encoding said antibodies and derivatives, the cells and pharmaceutical compositions containing them, in particular for their use in cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
This invention relates to a new stationary phase carrying boron clusters. Target molecules can interact with this stationary phase depending on the cluster type and the substituents. The stationary phase is suitable for SPE and chromatographic separations.
B01D 15/00 - Separating processes involving the treatment of liquids with solid sorbentsApparatus therefor
B01J 39/17 - Organic material containing also inorganic materials, e.g. inert material coated with an ion-exchange resin
B01J 39/19 - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
B01D 15/26 - Selective adsorption, e.g. chromatography characterised by the separation mechanism
68.
PROTEOLYSIS TARGETING CHIMERA (PROTAC) FOR DEGRADATION OF AURORA A-KINASE
The invention concerns a Proteolysis Targeting Chimera (PROTAC) or a pharmaceutically acceptable salt thereof for degradation of Aurora A-kinase in cells of a mammal which PROTAC has the chemical structure AAB-L-E3B, wherein AAB is a binding unit for Aurora A-kinase, L is a linker and E3B is a binding unit for E3-ubiquitin ligase Cereblon, wherein E3B comprises the structure of thalidomide or of one of its analogs lenalidomide, pomalidomide, and apremilast, wherein L comprises or consists of an alkyl ether residue or a polyalkyl ether residue or an alkyl ether residue or a polyalkyl ether residue in which at least one C—C bond is replaced by a C═C double bond, which polyalkyl ether residue has at least two ether groups or at least two ether groups in which one O-atom is replaced by an S-atom or a part of the O-atoms is replaced by S-atoms or wherein L comprises or consists of an alkyl thioether residue or a polyalkyl thioether residue or an alkyl thioether residue or a polyalkyl thioether residue in which at least one C—C bond is replaced by a C═C double bond, which polyalkyl thioether residue has at least two thioether groups, wherein L connects AAB and E3B via a chain of atoms having five to thirteen subsequently arranged atoms, wherein atoms of functional groups connecting the linker with AAB and E3B are not considered as part of said chain.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present invention discloses a therapeutic system for the topic, transdermal and transcutaneous application of carbon monoxide (CO), comprising: (i) an adhesive layer, (ii) a gas-permeable and liquid- and solid-impermeable membrane, (iii) a reaction chamber comprising a CO releasing molecule A, and (iv) a gas-impermeable backing layer, wherein the transdermal therapeutic system is configured that the CO releasing molecule A can be brought into contact with a CO release triggering compound B in the reaction chamber (iii). The therapeutic system can be used for the treatment of wounds, inflammatory diseases of the skin, and inflammatory diseases of subcutaneous skin tissue, joints and tendons.
Provided is a block copolymer comprising a polymer block (A) formed from repeating units of formula (I):
and a polymer block (B) formed from repeating units of formula (II):
as well as a hydrogel comprising the block copolymer.
The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in the treatment of solid cancers.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
72.
COMPOUND AND DIAGNOSTIC SYSTEM COMPRISING SAID COMPOUND FOR THE GUSTATORY DETECTION OF INFLAMMATIONS IN THE ORAL CAVITY
The present invention relates to compounds comprising denatonium linked to the C-terminus of a protease-sensitive peptide; or a salt thereof. The compounds are useful in the diagnosis of inflammatory conditions of the oral cavity.
C07C 237/04 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
Candida albicansin vivoC. albicansC. albicans infection, therapeutic application of mAb against Pra1 reduced clinical symptoms of the disease. Prophylactically, mAb against Tef1 protected mice from clinical disease and prolonged survival. The mABs of the present invention may also be efficacious in patients at risk or with already established IFD.
The present invention relates to a hybrid treatment of a tumor/cancer, said treatment comprises (i) targeting the resolution of transcription-replication conflicts in a tumor/cancer; or (ii) inducing in a tumor/cancer; and the use/administration of an immune cell, or a progenitor cell thereof, which is resistant against/less susceptible to said targeting/inducing. The immune cell, or progenitor cell thereof, is envisaged to target a/said (cell(s) of) a/said (solid) tumor/cancer. The present invention further relates to a respective immune cell, or a progenitor cell thereof. The present invention further relates to a pharmaceutical composition comprising the immune cell and/or a progenitor cell thereof and to a pharmaceutical composition, a kit or a combination (e.g. set of two/three components) comprising the immune cell and/or a progenitor cell thereof and a DDIA. The present invention further relates to methods of screening for a target of a DDIA which is resistant against/less susceptible to said DDIA or for an agent that is capable of inhibiting a target in a cell of a cancer/tumor and thereby inducing DNA damage and/or preventing resolution of DNA damage in said cell of a cancer/tumor; and that is incapable of inhibiting said target which is resistant against/less susceptible to said agent in an immune cell, or progenitor cell thereof, and thereby not inducing DNA damage and/or not preventing resolution of DNA damage in said immune cell or progenitor cell thereof.
The present invention relates to an agent for use in the treatment and/or prophylaxis of postischemic tissue damage, a pharmaceutical composition containing said agent, a method for the preparation of a medicament for the treatment and/or prophylaxis of postischemic tissue damage, and a method for the treatment and/or prophylaxis of postischemic tissue damage.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present invention relates to a method of diagnosing a human sepsis. The present invention further relates to a kit for diagnosing a human sepsis. The present invention also relates to a point-of-care device for performing a method of diagnosing a human sepsis. The present invention also relates to a use of a kit and/or a point-of-care device for a method of diagnosing a human sepsis. The present invention also relates to the use of a kit and/or a point-of-care device for a method of diagnosing a human sepsis. The method comprises stimulating a platelet-specific (hem-)ITAM receptor by adding a (hem-)ITAM receptor agonistic agent to a blood sample of a patient, wherein said agonistic agent comprises CRP-XL and/or convulxin, and measuring a platelet function level.
The present invention relates to a recombinant proteinaceous binding molecule wherein an Fc fragment is used as fusion partner and combined it with the hemibody technology. Furthermore, the invention relates to a heterodimeric recombinant proteinaceous binding molecule, as well as a method for producing the same, its use and a nucleic acid molecule encoding the recombinant proteinaceous binding molecule. The invention in particular provides a proteinaceous binding molecule that is capable of mediating target cell restricted activation of immune cells.
The invention relates to a CD84 inhibitor for use in treating or preventing of an ischemic disease and/or ischemic tissue damage, the use of a CD84 inhibitor for inhibiting CD84 mediated T cell migration in vitro and a method for screening for a CD84 inhibitor.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention relates to a set of polypeptides and its uses. In particular, the present invention relates to a set of polypeptides whereby this set comprises two polypeptides each of which comprises a targeting moiety “T” binding to an antigen “A” and a fragment of “F” of a functional domain, wherein said two polypeptides are not associated with each other in absence of a substrate that has “A” at (on) its surface and wherein, upon dimerization of “F”, the resulting dimer becomes functional. Furthermore, medical and diagnostic uses of said set are described. Moreover, the present invention relates to nucleic acid molecule(s) encoding said set of polypeptides. The present invention also relates to a vector comprising the nucleotide sequence of nucleic acid molecule(s) encoding said set of polypeptides. Furthermore, the present invention relates to pharmaceutical compositions comprising said set of polypeptides. Moreover, the present invention relates to a kit comprising said set of polypeptides.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
80.
DEVICE FOR FABRICATING A PERFUSABLE THREE-DIMENSIONAL TISSUE CONSTRUCT
The invention relates to a device for fabricating a perfusable three-dimensional tissue construct as well as to its manufacture and use. The device comprises a chamber in which the tissue construct may be cultivated, the chamber comprising an inlet and an outlet for perfusing the tissue construct, and a sacrificial scaffold fixed in the chamber. The sacrificial scaffold comprises a thermo-responsive polymer, the thermo-responsive polymer being not dissolvable in water at human body temperature and becoming dissolvable in water at a temperature below 30°C, preferably below 25°C. The sacrificial scaffold comprises at least one filament extending from the inlet to the outlet such that dissolution of the sacrificial scaffold provides for a liquid channel from the inlet to the outlet. The sacrificial scaffold seals the inlet and/or the outlet such that dissolution of the sacrificial scaffold after receiving a cultivation matrix in the chamber provides for a liquid channel from the inlet to the outlet through the cultivation matrix.
The invention refers to an implant device (10), in particular to a pubic symphysis implant device, and to an implant system (50) comprising two such implant devices (10-1, 10-2). The implant device (10) of the invention comprises a bent body (11) comprising a curved middle portion (12) and two lateral arms (14a, 14b) extending away from the middle portion (12) and being mutually joined by the middle portion (12), and at least one guiding element defining at least one guiding path along which a tensioning element (40) can be guided. The invention further refers to method of fixating together a first bone or bone part and a second bone or bone part, for example for re-joining a disjoined pubic symphysis, using such an implant system (50), in particular by placing each of the two implant devices (10-1, 10-2) on corresponding bones or bone parts and by pulling the two implant devices (10-1, 10-2) towards each other by tensioning a tensioning element (40) guided along the at least one guiding path of each of the two implant devices (10-1, 10-2).
The present disclosure provides a binding molecule that specifically binds TNFR2, but not TNFR1. Preferably the binding molecule is an FcyR-independent agonist of TNFR2 and more preferably has a valency of at least two for binding TNFR2. The binding molecules have a variety of uses including diagnostic and therapeutic. The ability of the binding molecules to be able to modulate immune responses means that they are particularly suited for treating autoimmune diseases, or inflammatory conditions.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
83.
ULTRAMODULAR IGG3-BASED SPACER DOMAIN AND MULTI-FUNCTION SITE FOR IMPLEMENTATION IN CHIMERIC ANTIGEN RECEPTOR DESIGN
The invention generally relates to immunotherapy using immune cells such as chimeric antigen receptor (CAR)-engineered T cells. In particular, the invention relates to immunotherapy using chimeric antigen receptor (CAR)-engineered T cells that carry a novel, IgG3-Hinge-based spacer domain, allowing a finely modulated response to target antigens. In addition, the invention relates to the introduction of one or more IgG3-Hinge-based multi-function sites (MFs) into CARs and other immunoreceptors, allowing purification, stimulation, expansion and depletion of CAR T cells. The invention includes also the sequence of an antibody targeting this motif, allowing the execution of the before-mentioned functions.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Provided is a block copolymer comprising a polymer block (A) which comprises repeating units of formula (I) and a polymer block (B) which comprises repeating units of formula (II), formula (I) formula (II) wherein R1is methyl or ethyl, and R2222-phenyl. The copolymer of the present invention allows a rapid thermoresponsive inverse gelation to be achieved, yielding a hydrogel with viscoelastic solid-like properties, as well as shear thinning, rapid structure recovery and good strain resistance properties. The hydrogel can be favorably used in 3D printing applications.
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
86.
GDF-15 AS A DIAGNOSTIC MARKER TO PREDICT THE CLINICAL OUTCOME OF A TREATMENT WITH IMMUNE CHECKPOINT BLOCKERS
The present invention relates to methods for predicting the probability of a treatment response of a human cancer patient to an immune checkpoint blocker treatment e.g. with anti PD-1, and to methods for predicting the probability of survival of a human cancer patient following an immune checkpoint blocker treatment, and to apparatuses and kits which can be used in these methods.
In order to determine a rheological property of a fluid, the fluid is conveyed with a constant volume flow rate through a nozzle and the fluid strand thereby generated is deposited on a substrate. A relative movement takes place between the nozzle and the substrate at a forward feed velocity value. A contour of the liquid strand between the nozzle and the substrate is optically measured, and an extensional viscosity as a rheological property is deduced from knowledge of the volume flow rate, the forward feed velocity value and the contour of the fluid strand.
G01N 11/04 - Investigating flow properties of materials, e.g. viscosity or plasticityAnalysing materials by determining flow properties by measuring flow of the material through a restricted passage, e.g. tube, aperture
G01N 11/08 - Investigating flow properties of materials, e.g. viscosity or plasticityAnalysing materials by determining flow properties by measuring flow of the material through a restricted passage, e.g. tube, aperture by measuring pressure required to produce a known flow
G01N 11/00 - Investigating flow properties of materials, e.g. viscosity or plasticityAnalysing materials by determining flow properties
88.
Emission of Electromagnetic Radiation and Control of the Properties of the Emitted Electromagnetic Radiation
Provided is a device for emitting electromagnetic radiation. The device includes a first electrode, a second electrode, and an exciton recombination layer extending from the first electrode to the second electrode. The device is configured to relocate a recombination zone in the exciton recombination layer by changing an electric field between the first electrode and the second electrode, or to emit electromagnetic radiation through a transparent substrate.
H01L 33/14 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a carrier transport control structure, e.g. highly-doped semiconductor layer or current-blocking structure
89.
Method for detecting and/or identifying magnetic supraparticles using magnet particle spectroscopy or magnet particle imaging
Fraunhofer-Gesellschaft zur förderung der angewandten Forschung e.V. (Germany)
Julius-Maximilians-Universität Würzburg (Germany)
Inventor
Mandel, Karl-Sebastian
Müssig, Stephan
Wintzheimer, Susanne
Fidler, Florian
Haddad, Daniel
Hiller, Karl-Heinz
Abstract
The invention relates to a method for detecting and/or identifying magnetic supraparticles using magnet particle spectroscopy (MPS) or magnet particle imaging (MPI), wherein magnetic supraparticles are provided, each of which contains a plurality of magnetic nanoparticles and which have a specific composition and/or structure. The magnetic supraparticles are exposed to at least one magnetic field, whereby at least one voltage and/or a voltage curve is induced based on the magnetic moment of the magnetic supraparticles. The at least one voltage and/or the voltage curve is detected as at least one measurement signal, and at least one spectrum is generated from the at least one measurement signal, said spectrum containing harmonics, each of which has an amplitude and a phase. The magnetic supraparticles are (uniquely) detected and/or identified using the at least one generated spectrum.
G01R 33/12 - Measuring magnetic properties of articles or specimens of solids or fluids
G01N 27/72 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables
90.
BIOCOMPATIBLE COMPOSITE MEMBRANE, METHOD FOR FABRICATING THE MEMBRANE, BIOREACTOR AND METHOD FOR INVESTIGATING CELLS ATTACHED TO THE BIOCOMPATIBLE COMPOSITE MEMBRANE
In various embodiments a biocompatible composite membrane for in vitro cell culturing comprising a first material, which is non-water soluble and a water soluble second material is provided, wherein the composite membrane comprises a porous scaffold and a filling layer, the scaffold comprising the first material and the filling layer comprising the second material. Further, a method for fabricating the membrane, a bioreactor for use of the membrane in cell-stretch experiments and a corresponding method for investigating cells attached to the biocompatible composite membrane are also provided.
A system for one-sided measuring a presence of magnetic particles in a probe volume comprises a one-sided coil assembly and a current controller, wherein the one-sided coil assembly is arranged around a central coil assembly axis for generating a rotating magnetic field distribution and comprises at least 3, preferably at least 4, circumferentially distributed coil assembly sectors, wherein the current controller is configured to generate a time varying current in each of said coil assembly sectors, said time varying current comprising a periodic modulation with a rotation frequency and phase shifted between adjacent coil assembly sectors to generate a magnetic field rotating in a plane perpendicular to the coil assembly axis, said magnetic field rotating with a rotation frequency associated with a frequency of said periodic modulation, and wherein the system is configured for measuring said presence of magnetic particles in said probe volume with said one-sided coil assembly.
The present invention relates to an anti-GDF15 antibody and to a dosage regimen for the treatment of cancer in a human patient using the anti-GDF15 antibody. The present inventors identified a mechanism by which GDF-15 blocks adhesion and transgression of predominantly T-lymphocytes into tissues. Hence, a novel treatment approach has been established by the present invention that facilitates effector T cell entry into tumor tissue upon blockage of GDF-15 using the antibody of the present invention thereby allowing the treatment of cancer in human patients.
The Sleeping Beauty (SB) transposon is an efficient non-viral tool for inserting transgenes into cells. Its broad utilization in gene therapy has been hampered by uncontrolled transposase gene activity and the inability to use transposase protein directly. The present invention concerns the finding that SB transposase spontaneously penetrates mammalian cells and can be delivered with transposon DNA to gene-modify various cell lines, embryonic, hematopoietic and induced pluripotent stem cells. The invention provides methods and compounds to apply the cell penetrating function of transposase in methods of genetically engineering cells as well as using the transposase as a shuttle for delivering cargo into a target cell or even into a target cell organelle. Genomic integration frequency can be titrated using the technology of the invention, which adds an additional layer of safety, opening opportunities for advanced applications in genetic engineering and gene therapy.
G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfacesMaterials therefor, e.g. comprising photoresistsApparatus specially adapted therefor
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
B82Y 40/00 - Manufacture or treatment of nanostructures
95.
ROR1-SPECIFIC CHIMERIC ANTIGEN RECEPTORS (CAR) WITH HUMANIZED TARGETING DOMAINS
The invention relates to chimeric antigen receptors (CAR) with a humanized targeting domain specific to the antigen ROR1. The invention encompasses the polynucleotides, vectors encoding said CARs and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
The present invention relates to a lymphocyte, modified to exhibit a reduced BCL2L11 level and/or an increased BATF3 level. The invention also relates to a method for producing such lymphocytes and a pharmaceutical composition comprising such lymphocytes. The lymphocytes and the pharmaceutical composition of the present invention may be used in methods for treating a disease in a patient.
The present invention provides live-attenuated bacterium of the genus Salmonella comprising a recombinant plasmid encoding a fusion protein, wherein the fusion protein comprises a coronavirus antigen and an adjuvant peptide.
C07K 14/28 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Vibrionaceae (F)
C07K 14/22 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Neisseriaceae (F), e.g. Acinetobacter
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The present invention relates to a siglec-6-binding polypeptide that comprises or consists of an antibody or a fragment thereof binding siglec-6 or comprises or consists of a siglec-6- binding chimeric antigen receptor (CAR), a polynucleotide encoding the siglec-6-binding polypeptide, an expression vector comprising the polynucleotide, an immune cell comprising the polypeptide, polynucleotide or expression vector, a method for producing immune cells and a pharmaceutical composition comprising immune cells. The immune cells and the pharmaceutical composition of the present invention may be used in methods for treating a disease, such as cancer, in a patient.
The present invention provides live-attenuated bacterium of the genus Salmonella comprising a recombinant plasmid encoding a fusion protein, wherein the fusion protein comprises a coronavirus antigen and an adjuvant peptide.
FUNDACIÓN INSTITUTO MADRILEÑO DE ESTUDIOS AVANZADOS EN NANOCIENCIA (IMDEA NANOCIENCIA) (Spain)
JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (Germany)
UNIVERSITAT AUTÒNOMA DE BARCELONA (UAB) (Spain)
Inventor
Llobet Dalmases, Antoni
Gimbert Suriñach, Carolina
Maseras Cuni, Feliu
Moonshiram, Dooshaye
Gil Sepulcre, Marcos
Shi, Yuanyuan
Hoque, Asmaul
Matheu Montserrat, Roc
De Aguirre Fondevila, Adiran
Sala Román, Xavier
Schindler, Dorothee
Würthner, Frank
Abstract
The present invention relates to a method for the preparation of a solid-supported catalyst wherein a catalytically active material is anchored on a surface of a solid material, wherein the catalytically active material comprises a plurality of moieties comprising a catalytically active metal coordination complex comprising a ligand arranged for interacting with the surface of a solid material through non-covalent interactions. The invention also relates to compounds useful in said method, compositions therefrom, an electrode therefrom and a device comprising such electrode. The invention also relates to a high yielding process for water oxidation taking place at neutral pH using an electrode according to the invention. The support preferably comprises carbon nanotubes and the preferred compounds are oligomeric Ru complexes, with L1=4,4'-bipyridine or 1,4-di(pyridin-3-yl)benzene as bridging ligands and L2=2,2'-bipyridine-6,6'-dicarboxylate (bda) or [2,2':6', 2"-terpyridine]- 6,6'-dicarboxylate (tda) as chelating ligands.
patents
